All In Biotech

Drug Trial Radar · NCT03789656

An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)

An Open Label Exploratory Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients With Acromegaly Treated With Somatostatin Analogue Based Treatment Regimens (ACROBAT Edge)

Last checked: Nov 20, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

47

Actual

Start

Mar 12, 2019

Primary completion

Aug 3, 2020

Study completion Aug 31, 2020

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Dec 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment regimens.

Conditions

  • Acromegaly

Interventions

  • PaltusotineDrug

    Paltusotine, capsules, once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) LevelTime frame: 13 Weeks

Locations

26 sites in 12 countries. Site status is shown where the registry gives one.

  • UCLA Gonda Diabetes Center

    Los Angeles, California

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • OHSU Northwest Pituitary Center

    Portland, Oregon

  • Allegheny Endocrinology Associates

    Pittsburgh, Pennsylvania

  • CETI - Centro de Estudos em Terapias Inovadoras

    Curitiba, Brazil

  • Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ) Centro de Pesquisa em Neuroendocrinologia

    Rio de Janeiro, Brazil

  • CPQuali Pesquisa Clinica

    São Paulo, Brazil

  • LMU Clinic of University of Munich

    Munich, Germany

  • General Hospital of Athens "Evangelismos"

    Athens, Greece

  • General Hospital of Athens "Gennimatas"

    Athens, Greece

  • General Hospital of Athens "Laiko"

    Athens, Greece

  • General Hospital of Athens "Ippokratio"

    Thessaloniki, Greece

  • Military Health Center, Division of Endocrinology

    Budapest, Hungary

  • Semmelweis University Faculty of Medicine

    Budapest, Hungary

  • University of Pécs Medical School

    Pécs, Hungary

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Italy

  • Waitemata District Health Board, North Shore Hospital

    Takapuna, New Zealand

  • Endocrine, Diabetes and Research Centre, Wellington Hospital

    Wellington, New Zealand

  • Clinic of Endocrinology Independent Public Health Care Centre University Hospital in Kracow

    Krakow, Poland

  • National Institute of Endocrinology "C. I. Parhon"

    Bucharest, Romania

  • Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases

    Belgrade, Serbia

  • University Hospital Bratislava

    Bratislava, Slovakia

  • University Hospitals Coventry and Warwickshire NHS Trust

    Coventry, United Kingdom

  • Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.